In addition to clinical findings in medullary thyroid cancer evaluation, RET proto-oncogene mutation screening is highly recommended to determine genotype-phenotype risks and to distinguish between sporadic and familial cases in terms of maintenance of the disease. Here, RET is linked to medullary thyroid gland carcinoma.